Related Experiment Video

Updated: Jun 24, 2025

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death
09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

8.6K

Inhibition of β2-adrenergic receptor regulates necroptosis in prostate cancer cell

Shiqi Wu1, Meixi Li1, Fangfang Chen1

  • 1Institution of Life Science, Chongqing Medical University, Chongqing, China.

Heliyon
|June 7, 2024
PubMed

Insights

Inhibiting beta-2 adrenergic receptor (β2AR) promotes cancer cell death via necroptosis. This targeted approach effectively suppresses prostate cancer cell proliferation by activating RIP/MLKL pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Pathways

Background:

  • Prostate cancer is a leading male malignancy impacting reproductive health.
  • Promoting cancer cell necroptosis is a validated strategy for inhibiting tumor growth.
  • The role of beta-2 adrenergic receptor (β2AR) in prostate cancer progression requires further elucidation.

Purpose of the Study:

  • To investigate the effect of β2AR inhibition on prostate cancer cell proliferation.
  • To determine the mechanism by which β2AR suppression impacts cancer cell death.
  • To explore the potential of targeting β2AR as a therapeutic strategy for prostate cancer.

Main Methods:

  • Lentivirus-mediated knockdown of β2AR in prostate cancer cell lines (PC-3, DU-145).
  • Assessment of cell proliferation, clone formation, and necrosis rates (flow cytometry, transmission electron microscopy).
  • Analysis of necroptosis-associated proteins (RIP, MLKL, RIPK3) via Western blot, immunofluorescence, and co-immunoprecipitation.

Main Results:

  • β2AR knockdown significantly increased clone formation and elevated RIP and MLKL protein/mRNA levels.
  • Propranolol treatment induced necrotic morphology, and combined β2AR suppression with necroptosis inhibitors enhanced proliferation suppression and necrosis.
  • Co-immunoprecipitation confirmed an interaction between β2AR and RIP; elevated RIP/MLKL in xenograft tumors from sh-β2AR group.

Conclusions:

  • Inhibition of β2AR suppresses prostate cancer cell proliferation.
  • This suppression is mediated through the RIP/MLKL-dependent necroptosis pathway.
  • Targeting β2AR represents a promising therapeutic avenue for prostate cancer treatment.
Keywords:
NecroptosisProstate cancerβ2AR

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.7K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.6K
Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.4K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K